Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 9/20 | 0.60 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.59 |
| ▸ | POLB | P06746 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.52 |
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.52 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | NPY2R | P49146 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 5/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.48 |
| ▸ | ATM | Q13315 | 1/20 | 0.48 |
| ▸ | DGAT1 | O75907 | 2/20 | 0.47 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.46 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | PANK3 | Q9H999 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL596528 | 0.89 | MAPT (0.62) | MAPTL3MBTL1POLBALDH1A1LMNA | |
| SCHEMBL4389301 | 0.85 | MAPT (0.46) | MAPTL3MBTL1POLBALDH1A1LMNA | |
| SCHEMBL595972 | 0.84 | MAPT (0.69) | MAPTL3MBTL1POLBALDH1A1LMNA | |
| SCHEMBL29772055 | 0.84 | MAPT (0.52) | MAPTL3MBTL1POLBALDH1A1LMNA | |
| SCHEMBL16984992 | 0.84 | L3MBTL1 (0.46) | MAPTL3MBTL1POLBALDH1A1LMNA | |
| SCHEMBL3542849 | 0.84 | MAPT (0.64) | MAPTL3MBTL1POLBALDH1A1LMNA | |
| SCHEMBL3542851 | 0.84 | MAPT (0.64) | MAPTL3MBTL1POLBALDH1A1LMNA | |
| SCHEMBL4399969 | 0.83 | MAPT (0.70) | MAPTPOLBALDH1A1LMNAMAPK1 | |
| SCHEMBL29772093 | 0.83 | MAPT (0.50) | MAPTL3MBTL1POLBALDH1A1LMNA | |
| SCHEMBL24880628 | 0.82 | DGAT1 (0.49) | L3MBTL1ALDH1A1HPGDKMT2ADGAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2014140241-A1 | PYRIDINE DERIVATIVES AS DGAT-1 INHIBITORS | INTERVET INTERNATIONAL B.V. (NL) | 2014-09-18 | — | — | WO | disclosed |
| WO-2014140241-A1 | PYRIDINE DERIVATIVES AS DGAT-1 INHIBITORS | INTERVET INTERNATIONAL B.V. (NL) | 2014-09-18 | — | — | WO | disclosed |
| US-8772494-B2 | N-aryl piperidine substituted biphenylcarboxamides as inhibitors of apolipoprotein b | JANSSEN PHARMACEUTICA N.V. (BE) | 2014-07-08 | — | — | US | disclosed |
| US-8772494-B2 | N-aryl piperidine substituted biphenylcarboxamides as inhibitors of apolipoprotein b | JANSSEN PHARMACEUTICA N.V. (BE) | 2014-07-08 | — | — | US | disclosed |
| US-8258304-B2 | N-aryl piperidine substituted biphenylcarboxamides | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-09-04 | — | — | US | disclosed |
| US-20090156623-A1 | N-ARYL PIPERIDINE SUBSTITUTED BIPHENYLCARBOXAMIDES | MEERPOEL LIEVEN | 2009-06-18 | — | — | US | disclosed |
| EP-1536796-B1 | N-ARYL PIPERIDINE SUBSTITUTED BIPHENYLCARBOXAMIDES AS INHIBITORS OF APOLIPOPROTEIN B SECRETION | JANSSEN PHARMACEUTICA NV (BE) | 2008-02-13 | — | — | EP | disclosed |
| US-20070099934-A1 | N-aryl piperidine substituted biphenylcarboxamides as inhibitors of apolipoprotein b | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-05-03 | — | — | US | disclosed |
| US-20070099934-A1 | N-aryl piperidine substituted biphenylcarboxamides as inhibitors of apolipoprotein b | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-05-03 | — | — | US | disclosed |
| US-20060040989-A1 | N-aryl piperidine substituted biphenylcarboxamides as inhibitors of apolipoprotein b secretion | JANSSEN PHARMACEUTICA, N.V. (BE) | 2006-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156623-A1 | N-ARYL PIPERIDINE SUBSTITUTED BIPHENYLCARBOXAMIDES | LIPC, PNLIP, GPR119 | MAPT 4498/4885L3MBTL1 4535/4885POLB 2689/4885 |
| US-20070099934-A1 | N-aryl piperidine substituted biphenylcarboxamides as inhibitors of apolipoprotein b | APOB, PNLIP, LIPC | MAPT 4151/4885L3MBTL1 4022/4885POLB 876/4885 |
| US-20060040989-A1 | N-aryl piperidine substituted biphenylcarboxamides as inhibitors of apolipoprotein b secretion | APOB, PNLIP, LPL | MAPT 4272/4885L3MBTL1 4314/4885POLB 1402/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.